Every 8-K that Cross Country Healthcare Inc (CCRN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CCRN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CCRN filings page.
Cross Country Healthcare, Inc. completed its previously announced merger with KL Criss Cross Merger Sub, Inc., an affiliate of Knox Lane, on July 21, 2026. Each share of Company common stock was converted into the right to receive $13.25 in cash per share, without interest and subject to withholding taxes. Outstanding restricted stock and performance stock awards were vested, canceled and cashed out based on the same $13.25 price, with performance awards settled at the greater of target or actual performance. Parent funded the transaction through a combination of cash on hand, including Company balance sheet cash, equity financing and debt financing, and the Company discharged all obligations under its ABL Credit Agreement dated October 25, 2019.
As of the merger’s effective time, Cross Country Healthcare became a wholly owned subsidiary of Parent, a change in control occurred, and holders of common stock ceased to have shareholder rights other than the right to receive the cash merger consideration. Trading in the Company’s shares on Nasdaq was suspended on July 21, 2026, with a Form 25 to remove the listing and an intended Form 15 to terminate registration and suspend SEC reporting. The pre-merger board members, including co‑founder and CEO Kevin C. Clark, resigned, and the directors and officers of Merger Sub assumed those roles. Joel Tremblay was appointed Chief Executive Officer, and the Company’s locums division was acquired by All Star Healthcare Solutions, a Knox Lane portfolio company.
Cross Country Healthcare, Inc. stockholders approved the proposed merger under the May 6, 2026 Merger Agreement with KL Criss Cross Intermediate, LLC and its merger subsidiary at a July 16, 2026 special meeting. As of the June 12, 2026 record date, 32,306,484 shares of common stock were outstanding, and holders of 23,378,853 shares, or about 72.36%, were present or represented, constituting a quorum.
Stockholders adopted the Merger Agreement with 23,356,105 votes for, 12,309 against and 10,439 abstentions, and approved on an advisory basis the merger-related compensation for named executive officers. Because the merger proposal passed, a vote on adjournment was not needed. Subject to customary closing conditions and regulatory approvals, the merger is expected to close in the third quarter of 2026, after which Cross Country Healthcare will become a wholly owned subsidiary of the buyer, will no longer be publicly held, and its common stock will be delisted from NASDAQ and deregistered under the Exchange Act.
Cross Country Healthcare, Inc. reports that the required waiting periods under the Hart-Scott-Rodino Act for its planned merger with KL Criss Cross Intermediate, LLC and the sale of its locums business to All Star Healthcare Solutions expired at 11:59 p.m. Eastern Time on June 22, 2026. This expiration removes a major regulatory condition to closing these transactions, which remain subject to other customary closing conditions. The merger is expected to close in the third quarter of 2026, and a special shareholder meeting to vote on the merger is scheduled for July 16, 2026 at 12:00 p.m. Eastern Time.
Cross Country Healthcare, Inc. reported first quarter 2026 revenue of $241.1 million, down 18% from a year earlier but up 2% from the prior quarter, reflecting modest sequential improvement after a sharp industry slowdown. Consolidated gross profit margin was 19.7%, slightly below both prior year and prior quarter levels.
The company posted a net loss attributable to common stockholders of $4.3 million, versus a $0.5 million loss a year ago and an $82.9 million loss in the prior quarter. Adjusted EBITDA was $3.9 million, or 1.6% of revenue. Cross Country ended the quarter with $105.6 million in cash, no debt, and repurchased about 0.7 million shares for $5.8 million. The release notes a pending merger with KL Criss Cross Intermediate, after which the stock is expected to be delisted and deregistered.
Cross Country Healthcare, Inc. agreed to be acquired by Knox Lane in an all-cash merger. Stockholders are expected to receive $13.25 per share in cash, valuing the deal at about $437 million and reflecting premiums of roughly 31% to the last close and 45% to the 90-day volume-weighted average price.
The merger must be approved by a majority of Cross Country stockholders and clear antitrust and other customary conditions. If completed, Cross Country will become a wholly owned subsidiary of Knox Lane, its shares will be delisted and deregistered, and the company has canceled its Q1 2026 earnings call and 2026 annual meeting in light of the proposed transaction.
Cross Country Healthcare, Inc. announced it will hold a quarterly conference call to discuss its first quarter 2026 financial results on Thursday, May 7, 2026 at 5:00 p.m. Eastern Time. The company intends to issue its earnings press release after the market close that same day.
The call will be available via live webcast on the company’s investor relations website and by telephone using the provided U.S. and international dial-in numbers and passcode. Telephone and webcast replays will be accessible from May 7 through May 21, 2026. The filing also reiterates that the furnished press release is not deemed filed for liability purposes under the Exchange Act.
Cross Country Healthcare, Inc. reported that its Board of Directors appointed Amiee Hawkins as Chief Operating Officer, effective March 28, 2026. She previously served as Chief Solutions and Operations Officer and has held a series of senior operational roles since joining the company in 2014.
The company stated there were no new or amended agreements or changes to Ms. Hawkins’ compensation in connection with this appointment. It also disclosed that she has no family relationships with directors or executive officers and no material related-party transactions requiring disclosure.
Cross Country Healthcare, Inc. detailed the exit arrangements for former Chief Information Officer Phil Noe. As previously disclosed, he ceased serving as CIO effective March 10, 2026. On March 16, 2026, the company and Mr. Noe entered into a Separation Agreement and an Independent Contractor Agreement.
Under the Separation Agreement, Mr. Noe will receive $205,975 in severance, equal to six months of his current base salary, paid in bi-weekly installments over six months, provided he does not revoke his waiver and release within seven days of signing. Separately, the Consulting Agreement engages him from March 11, 2026 through May 31, 2026 to provide technology and infrastructure consulting services at a rate of $198.04 per hour, with early termination permitted by mutual written agreement.
Cross Country Healthcare, Inc. announced leadership changes in its finance and technology functions. Effective March 10, 2026, James V. Redd III will step down as Senior Vice President and Chief Accounting Officer, and Phil Noe will step down as Chief Information Officer. The company states that neither departure results from any dispute or disagreement, including on accounting practices or financial reporting.
The Board appointed longtime employee Marvin Veizaga as Senior Vice President and Chief Accounting Officer, effective the same date. Veizaga has been with the company since 2015 in increasingly senior controller roles and previously worked as a Senior Auditor at Deloitte & Touche LLP. Under a new Letter Agreement, his base salary will be $340,000, with an annual short-term incentive bonus target of 50% of base salary and an annual long-term equity incentive target of 50% of base salary. The company notes there are no related-party arrangements or family relationships tied to his appointment.
Cross Country Healthcare reported sharply weaker results for Q4 and full year 2025 as demand for healthcare staffing continued to soften and merger-related impacts weighed on earnings. Fourth quarter revenue was $236.8 million, down 24% from a year ago and 5% from the prior quarter, while full-year revenue fell 22% to $1.05 billion.
Profitability deteriorated significantly. Q4 net loss attributable to common stockholders widened to $82.9 million, and the full-year net loss reached $94.9 million, or $2.93 per diluted share. Results were heavily affected by a $77.9 million non-cash impairment of goodwill and trade names and a $29.6 million valuation allowance against deferred tax assets, both tied to a decline in the company’s market value after the Aya merger agreement was terminated.
On an adjusted basis, Q4 EBITDA was $4.1 million, or 1.7% of revenue, down from $9.3 million and a 3.0% margin a year earlier. Full-year adjusted EBITDA dropped to $26.8 million, or a 2.5% margin, from $49.1 million and 3.7%. Management’s outlook for Q1 2026 calls for revenue of $235 million to $240 million and adjusted EBITDA of $4.0 million to $5.0 million, implying revenue declines of roughly 18% to 20% year-over-year and substantially lower adjusted earnings.
Cross Country Healthcare, Inc. is providing an update on investor outreach activities. The company announced it is scheduled to participate in the Truist Securities Virtual Human Capital Conference on March 12–13, 2026 and the Oppenheimer 36th Annual Healthcare MedTech & Services Conference on March 16–19, 2026.
At both events, executives including Executive Vice President & Chief Financial Officer William J. Burns and Vice President of Investor Relations Josh Vogel will hold one-on-one meetings with investors, with no formal presentations planned.
Cross Country Healthcare, Inc. is informing investors about its upcoming fourth quarter and full year 2025 earnings conference call. The call will take place on Wednesday, March 4, 2026 at 5:00 p.m. Eastern Time, with an earnings press release expected after market close that day.
The call will be accessible via live webcast on the company’s investor relations website at ir.crosscountry.com and by phone using listed U.S. and international dial-in numbers with the passcode “Cross Country.” A replay will be available online and by telephone from March 4 through March 18.
The filing presents this information under a Regulation FD disclosure item and includes a furnished press release as an exhibit, outlining the call logistics and offering a brief description of Cross Country Healthcare’s technology-driven healthcare workforce solutions business.
Cross Country Healthcare, Inc. has set May 11, 2026 as the date for its virtual-only 2026 Annual Meeting of Stockholders. Details on the meeting time and website will appear in the proxy statement, which is expected to be made available on or about March 31, 2026.
Stockholder proposals for inclusion in the proxy statement under Rule 14a-8 must reach the company’s principal executive office by the close of business on March 11, 2026. Under the company’s bylaws, notices to propose other business or nominate directors must be delivered by February 10, 2026.
To use the universal proxy rules for director nominees other than the company’s, stockholders must provide the information required by Rule 14a-19 by March 12, 2026. All materials are to be sent to the Corporate Secretary at the Boca Raton, Florida headquarters.
Cross Country Healthcare announced a major leadership change as President and Chief Executive Officer John A. Martins separated from the company effective December 14, 2025, and stepped down from the board, which was reduced from seven to six members. The board appointed current chairman, former CEO, and co‑founder Kevin C. Clark as President and CEO, effective the same date, and he will continue to serve as chairman.
Under his employment agreement, Martins will receive cash severance equal to two years of his base salary of $875,000 plus two times his average actual bonus over the prior three years, paid over 24 months, along with up to 24 months of continued benefits if elected. All of his unvested equity awards will fully vest, with outstanding performance share awards vesting at target. The company plans to finalize an employment agreement setting Clark’s compensation and intends to file an amendment when those terms are determined.
On September 25, 2025 Cross Country Healthcare, Inc. announced its Board set the 2025 virtual-only Annual Meeting for December 9, 2025, which is more than 30 days after last year’s meeting. The meeting will only occur if the pending merger with Aya Healthcare, Inc. (the Aya Merger) is not completed beforehand; the company continues to expect the Aya Merger to close in the fourth quarter of 2025. If the merger is completed first, Cross Country will become a wholly owned subsidiary of Aya and the Annual Meeting will not be held. The company set a deadline of October 10, 2025 for stockholder proposals, nominations and Rule 14a-19 universal proxy notices, and said the proxy statement will be made available by or prior to October 30, 2025.
Cross Country Healthcare, Inc. disclosed that under its Merger Agreement with Aya Holdings II Inc., the contractual “End Date” for completing their planned merger was automatically extended from September 3, 2025 to December 3, 2025. All other terms of the Merger Agreement remain unchanged.
The company and Aya have each certified to the U.S. Federal Trade Commission that they have substantially complied with the agency’s “Second Request” for additional information related to the transaction. Subject to customary closing conditions and required regulatory approvals, the merger is now expected to close in the fourth quarter of 2025.